[go: up one dir, main page]

WO2002066979A1 - Procede de detection d'un antigene responsable de l'asthme - Google Patents

Procede de detection d'un antigene responsable de l'asthme Download PDF

Info

Publication number
WO2002066979A1
WO2002066979A1 PCT/JP2002/001403 JP0201403W WO02066979A1 WO 2002066979 A1 WO2002066979 A1 WO 2002066979A1 JP 0201403 W JP0201403 W JP 0201403W WO 02066979 A1 WO02066979 A1 WO 02066979A1
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
cells
asthma
bronchial asthma
causative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/001403
Other languages
English (en)
Japanese (ja)
Inventor
Akio Mori
Kazuo Akiyama
Kazutoh Takesako
Ikunoshin Kato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takara Bio Inc
Original Assignee
Takara Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Bio Inc filed Critical Takara Bio Inc
Priority to JP2002566654A priority Critical patent/JPWO2002066979A1/ja
Publication of WO2002066979A1 publication Critical patent/WO2002066979A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Definitions

  • the present invention relates to a method for identifying a causative antigen, a kit for identifying a causative antigen, and a therapeutic or prophylactic agent for bronchial asthma. Further, the present invention relates to a method for detecting an antigen causing bronchial asthma.
  • Bronchial asthma mainly occurs in childhood, and about 2/3 of the group of atopy-type patients who have IgE antibodies against antigens such as ticks accounts for about 2/3 of the population.
  • Non-atopic (also known as endogenous, infectious) patient groups account for approximately 1 Z 3 of the disease.
  • Atopic bronchial asthma is recognized as an immediate hypersensitivity caused by IgE antibodies to antigens and mast cells.
  • treatment with anti-inflammatory drugs such as steroid drugs and anti-allergic drugs and bronchodilator drugs and treatment to suppress airway hyperresponsiveness, as well as binding to patient-derived IgE antibodies It is more effective to avoid the antigen identified as the causative factor and to perform desensitization therapy using the antigen by identifying the antigen and further identifying the causative antigen by skin test.
  • the method of identifying the causative factor is not yet known, and only treatment for suppressing airway hyperreactivity as symptomatic treatment is performed.
  • bronchial asthma is not just a transient immediate hypersensitivity as described above, but it is recognized that persistent eosinophilic inflammation is essential.
  • airway mucosa of patients with bronchial asthma has cell infiltration and inflammatory findings characterized by accumulation of eosinophils.
  • eosinophils Unlike normal inflammation, which is characterized by accumulation of monocytes, macrophages, and neutrophils, such as bacterial infections, eosinophils selectively accumulate, so they are called eosinophilic inflammation.
  • Eosinophils in bronchial asthma are seen in patients with bronchial asthma who have significant infiltration of activated helper T cells in the area of airway inflammation and the correlation between the number of eosinophils infiltrating the airway mucosa and the number of ⁇ cells.
  • CD4-positive helper T cells Kerm AB. ⁇ Helper '' (CD4 +) T cells and eosinophils in allergy and asthma
  • the present invention provides a method for identifying a causative antigen of bronchial asthma, particularly a non-atopic bronchial asthma, and a bronchial bronchi capable of easily and quickly identifying a causative antigen of bronchial asthma.
  • An object of the present invention is to provide a kit for identifying an antigen causing asthma, and a therapeutic or preventive agent for non-atopic bronchial asthma, which comprises an antigen causing bronchial asthma.
  • Another object of the present invention is to provide a method for detecting an antigen causing bronchial asthma, which can detect the presence of an antigen causing bronchial asthma in a test sample.
  • the present invention C 1 The amount of IL-15 produced from T cells due to the stimulation of the test substance was measured, and an increase in the amount of IL-15 production was observed as compared to T cells not stimulated with the test substance.
  • the test substance is identified as a causative antigen of bronchial asthma, a method for identifying a causative antigen of bronchial asthma,
  • the test substance is The identification method according to the above (1), which is identified as a causative antigen of asthma.
  • kits for identifying an antigen causing bronchial asthma comprising an antigen capable of increasing the amount of IL_5 produced from T cells upon stimulation;
  • bronchial asthma is non-atopic bronchial asthma
  • a therapeutic or prophylactic agent for non-atopic bronchial asthma comprising as an active ingredient all or a part of an antigen causing bronchial asthma;
  • a therapeutic or prophylactic agent for non-atopic bronchial asthma comprising an antifungal agent as an active ingredient
  • bronchi It is determined that an antigen causing asthma is present, the detection method according to the above (9), and the detection method according to the above (9) or (10), wherein the bronchial asthma is non-atopic bronchial asthma.
  • FIG. 1 is a graph showing the results of induction of IL-15 production from T cells by Candida-derived antigens.
  • the abscissa indicates the antigen derived from each Candida, and the ordinate indicates the difference between the case where the antigen was stimulated and the case of the control as IL-15 production amount (pgZml).
  • the numbers in the graph are the average IL-15 production masculine SE (measured average value of 8 cases).
  • FIG. 2 is a graph showing the results of T cell proliferation induction by Candida-derived antigens.
  • the horizontal axis describes the Candida-derived antigen, the 3 H- thymidine uptake by T cell proliferation in the vertical axis as a relative value to the control shown by 3 H- TdR uptake (SI).
  • the numbers in the graph are the average 3H-TdR uptake soil SE (mean average value of 8 cases).
  • the amount of 3H-TdR incorporation was determined by the following equation:
  • the present inventors have made it possible to identify the causative antigen of non-atopic bronchial asthma (hereinafter simply referred to as asthma), for which no report has been made on the identification of the causative antigen. Therefore, we presumed that non-atopic asthma was persistent eosinophilic inflammation, and focused on the cytokines involved in eosinophil accumulation.
  • atypical asthma is distinguished from non-atopic asthma in that IgE antibodies are involved (furthermore, an immediate asthmatic response (IAR) involving IgE antibodies occurs).
  • IAR immediate asthmatic response
  • the pathogenesis of the disease is completely different, but in atopic asthma, as in non-atopic asthma, an acid is understood as a late asthmatic response (LAR). Spheroid inflammation is observed.
  • the antigen responsible for atopic asthma is IgE antibody production.
  • an antigen that causes IL-5 production in an atopic asthmatic patient is a causative antigen of acute topic asthma. Therefore, it is possible to identify the antigen responsible for atopic asthma using the production of IL-15 from T cells by antigen stimulation as an indicator.
  • the present inventors can identify asthma-based antigens without distinguishing between atopic and non-atopic types by using IL-15 production from T cells by antigen stimulation as an index. And found that the present invention was completed. Therefore, according to the method for identifying asthma-causing antigens of the present invention, asthma-causing antigens that have been regarded as completely different diseases and that have been classified into two disease types, Athobi type 1 and non-Athby type, have been identified. Without such a distinction, identification can be performed simply and reliably using IL-5 production from T cells as an index. In particular, by examining IL-5 production from T cells from individuals (eg, patients) diagnosed with non-atopic asthma without production of IgE antibodies, non-atopic Its technical significance is extremely great because it allows identification of the antigen responsible for atopic asthma.
  • the method for identifying an asthma-causing antigen of the present invention comprises measuring the amount of IL-15 produced from T cells by stimulation of a test substance, and comparing the case of T cells not stimulated with the test substance. By comparison, when an increase in the amount of IL_5 production is observed, the test substance is identified as an antigen causing asthma.
  • test substance refers to a target substance that is evaluated for its IL-5 production effect on T cells, and includes any substance presumed to be involved in the development of asthma. It is not limited. Examples thereof include mites, house dust, fungi, pollens, pet epidermis, and components contained therein.
  • the test substance also includes a substance which has been known as a causative antigen of atopic asthma, but according to the identification method of the present invention, a causative antigen of non-atopic asthma can be identified. When such a substance is used as a test substance, it is possible to further obtain information on whether or not the substance is a causative antigen of non-atopic asthma.
  • ⁇ cells refers to an individual-derived biological tissue specimen (for example, ⁇ cells derived from peripheral blood, spleen, etc.), and preferably CD4 positive helper ⁇ cells derived from peripheral blood, which have been reported to be involved in the development of eosinophilic inflammation.
  • the T cells are preferably isolated from a biological tissue specimen, but need not necessarily be isolated.
  • peripheral blood mononuclear cells can be directly used in the identification method of the present invention.
  • An “individual” is preferably a mammal (eg, a dog, a cat, a pen, a dog, a human), and more preferably a human.
  • the stimulation of T cells by a test substance is performed, for example, by collecting peripheral blood mononuclear cells containing T cells from an individual according to a known method, adding a test substance thereto, and in the presence of the test substance, preferably 35 to It can be performed by incubating at 38 ° C for about 1 hour to 7 days.
  • the peripheral blood mononuclear cells are cultured in the same manner without adding the test substance and without stimulating with the test substance, to serve as a control.
  • the amount of IL-5 produced from the T cells is measured.
  • Such a measurement can be carried out by the ELISA method for measuring IL-5 protein mass, RT_PCR for quantifying the amount of mRNA, Northern hybridization, or the like.
  • the present invention is not particularly limited, but is preferably determined by the ELISA method.
  • As a result of the measurement when an increase in the production amount of IL-15 (pg / ml) from T cells stimulated with the test substance was observed as a substantial difference compared to the control, The substance is identified as the causative antigen of asthma.
  • the difference in the amount of IL-15 produced is expressed by specific numerical values, it is preferably 1 Opg / m1 or more, more preferably 20 pg / m1 or more, and still more preferably 5 Opg / m1 or more. If the difference in the amount of IL-15 production is less than 10 pg / ml, it does not necessarily indicate a substantial difference due to individual differences or the measurement limit of the amount of IL-5 production, etc. In any case, if the difference is not more than 10 pg / m1, the antigen causing asthma can be clearly identified.
  • the test substance is a cause of asthma
  • the amount of IL-15 produced from T cells in the control (S 1) and the amount of IL-5 produced from T cells cultured in the presence of the test substance (S 2) were each determined. Measure, subtract 32 from 31, and if the subtracted value is 1 O pg / ml or more, the test substance is identified as a causative antigen of asthma.
  • the temperature and period suitable for culturing T cells are the same as described above, and more specific culture conditions and the like may be in accordance with known ones.
  • a causative antigen specific to non-atopic asthma can be identified.
  • T cells derived from an individual diagnosed with non-atopic asthma may be used in accordance with the conventional determination of the type of asthma.
  • the cause antigens of asthma patients can be clarified, so that antigen evasion and desensitization therapy are effective for all asthma patients.
  • an antigen specific to non-atopic asthma is very effective for the treatment or prevention of the asthma.
  • the identification of the asthma-causing antigen is performed easily and quickly.
  • a kit for identifying an asthma-causing antigen includes an antigen capable of increasing the amount of IL-15 produced from T cells upon stimulation.
  • the antigen is not particularly limited as long as it can increase the amount of IL-15 produced from T cells by the stimulation, but it is preferable to use the method for identifying an asthma-causing antigen of the present invention.
  • the identified antigen include, for example, at least one selected from the group consisting of Candida-derived antigen, Candida-derived acidic protease, mite extract, and Derf 1, Derf II, and house dust, which are described in Examples below. Can be mentioned. It is preferable that the antigen is, for example, lyophilized and packaged from the viewpoint of preservation. The antigen must be suitable before use. It can be used after reconstitution in a carrier.
  • the antigen contained in the above kit can be added to the medium used for culturing T cells at a concentration in the range of 0.1 to 100 / g / m1, the form, content, There is no particular limitation on the concentration.
  • a lyophilized antigen or a high-concentration antigen solution that can be contained in the kit of the present invention may be dissolved and diluted to an appropriate concentration, and then added to the medium so that the concentration is within the above range. .
  • the kit may further optionally contain a reagent used for measuring the amount of IL-5 produced from T cells. Further, for example, when it is intended to measure the amount of IL-5 produced from T cells by a colorimetric method, it may contain various concentrations of IL-15 used for calibration.
  • Identification of the asthma-causing antigen using the kit can be performed according to the method of the present invention for identifying an asthma-causing antigen. That is, when the causative antigen is identified using the kit, the antigen contained in the kit is treated in the same manner as the test substance, and the causative antigen of asthma is identified in the same manner as in the above-described identification method. Since the kit contains various antigens capable of increasing the production of IL-15 from T cells in advance, for example, by identifying the causative antigen using the kit for asthma patients, Patient-specific causative antigens are easily identified.
  • the kit of the present invention can also serve as a diagnostic kit for non-atopic asthma.
  • a therapeutic or preventive agent for non-atopic asthma which contains all or a part of an asthma-causing antigen as an active ingredient.
  • a causative antigen those identified by the method for identifying an asthmatic causative antigen are preferable, and among them, a causative antigen specific to non-atopic asthma is preferable.
  • Therapeutic agent of the present invention specific examples of the causative antigen that can be suitably used in the prophylactic agent include the antigens exemplified in the kit.
  • the term “causal antigen” means all or a part of the causative antigen.
  • "part of the causal antigen” refers to at least a part of the causative antigen including a structure that determines the specificity and immunogenicity of the antigen-antibody reaction of the antigen, and is preferably an epitope or an antigenic determinant. Means part of the causative antigen.
  • the causative antigen may be a hapten bound to an appropriate carrier.
  • compositions include a causative antigen, one or more pharmaceutically acceptable carriers (eg, starch, lactose, sucrose, mannitol, carboxymethylcellulose, corn starch, etc.), and optionally other And those containing a therapeutic or prophylactic component.
  • a pharmaceutically acceptable carrier eg, starch, lactose, sucrose, mannitol, carboxymethylcellulose, corn starch, etc.
  • compositions include those suitable for oral (preferably inhalation), nasal, and parenteral (eg, subcutaneous, transdermal, intradermal, intramuscular, intravenous, and rectal administration). It can be adjusted as appropriate according to the symptoms of the individual who needs to administer the composition.
  • the compositions may, if desired, be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy.
  • compositions suitable for oral and / or nasal administration include, for example, capsules, tablets, powders or granules each containing a predetermined amount of the causative antigen as an active ingredient, as a solution or suspension in aqueous or non-aqueous liquid Alternatively, it can be provided as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
  • Compositions for inhalation may be provided in any manner known to be effective (eg, metered dose inhalers). Further, the composition may contain a known adjuvant (for example, cholera toxin, cholera toxin B subunit, and variants thereof).
  • compositions for parenteral administration include, for example, water-soluble and water-insoluble sterile injectable solutions which can contain antioxidants, buffers, bacteriostats, solutes which are isotonic with the blood of the individual to be dosed. And aqueous and non-aqueous sterile suspensions which may contain suspending and bulking agents.
  • the compositions may be presented in single or multidose containers, for example, sealed ampoules and vials, and added to a sterile liquid carrier immediately before use, for example, water for injection. It may be provided in lyophilized form, which only needs to be done.
  • a composition for rectal administration for example, it can be provided as a suppository in combination with a usual carrier such as polyethylene glycol.
  • the content of the asthma-causing antigen in the composition is not particularly limited, and can be appropriately adjusted as desired.
  • the preferred causal antigen content in the composition is preferably between 0.01 and 50 g / ml.
  • the dose of the therapeutic or prophylactic agent of the present invention is not particularly limited as long as the desired effects of the present invention can be obtained.
  • the dose is preferably administered orally or parenterally within the effective dosage range of the causative antigen, preferably from 0.2 ng to 0.1 mg / kg body weight per adult.
  • the dose of the causative antigen as an active ingredient is not limited to this range.
  • the administration method, the number of administrations, the administration period, and the like are not particularly limited.
  • the therapeutic or prophylactic agent of the present invention by producing an antibody against the causative antigen to be administered, neutralization of an antigen involved in the development of asthma in an individual, in particular, an antigen specific to non-atopic asthma Therefore, it is possible to effectively treat or prevent non-atopic asthma, which could not be effectively performed until now.
  • IgA and IgG are produced in the nasal discharge and oral cavity, and can effectively work for removing antigens around the bronchi. Therefore, the therapeutic or prophylactic agent of the present invention is effective for mucosal immunotherapy.
  • the causative antigen contained as an active ingredient in the therapeutic or prophylactic agent of the present invention is specific to non-atopic asthma
  • the therapeutic or prophylactic agent also functions as a diagnostic composition for non-atopic asthma I can do it.
  • a more effective therapeutic or preventive agent for non-atopic asthma can be provided.
  • the causative antigen is identified as a Candida-derived antigen
  • an effective antifungal agent eg, fluconazole, itraconazole, amphotericin B, etc.
  • a therapeutic or preventive agent for non-atopic asthma can be provided.
  • the root cause of asthma can be directly eliminated, so that a very excellent therapeutic or preventive effect can be obtained.
  • the therapeutic or prophylactic agent is also included in the present invention.
  • the therapeutic or prophylactic agent may contain only an antifungal agent as an active ingredient.However, from the viewpoint of expecting a therapeutic or preventive effect over asthma in general, as an active ingredient, an antigen causing asthma, Among them, those containing both the antigen causing non-atopic asthma are preferable.
  • the content of the antifungal agent in the therapeutic agent or the prophylactic agent is not particularly limited, and varies depending on each antifungal agent, and can be appropriately selected. However, a desired amount depends on the dosage form and the route of administration. What is necessary is just a content which can acquire an effect.
  • the dosage of the antifungal agent is generally, for example, preferably 1 g to 5 mg / kg body weight per day for an adult when intravenously injected into a human.
  • the production method and administration method of the therapeutic or prophylactic agent are the same as described above.
  • the detection method is to measure the amount of IL-15 produced in T cells that have been brought into contact with the test sample, and to compare this with the T cells that have not been brought into contact with the test sample (control).
  • a method for detecting an asthma-causing antigen wherein it is determined that an asthma-causing antigen is present in the test sample when an increase in the IL-15 production amount is observed.
  • Such a detection method can be performed according to the method for identifying an antigen causing asthma of the present invention. Wear.
  • the contact between the test sample and the T cells may be performed by using the test sample instead of the test substance in the step of stimulating the cells with the test substance in the identification method.
  • the test sample is not particularly limited as long as the presence of the test substance can be expected. For example, food, drinking water, domestic water, house dust, indoor and outdoor airborne substances, and the like can be mentioned.
  • the amount of IL-5 produced from the ⁇ cells is measured in the same manner. As a result of the measurement, when an increase in the amount of IL_5 produced from the cells in contact with the test sample was observed as a substantial difference compared to the control, the antigen causing asthma in the test sample was included in the test sample. Is determined to exist.
  • the specific numerical value of the difference in the amount of IL-5 production is the same as in the case of the identification method. Therefore, in a preferred embodiment of the method for detecting an antigen causing asthma of the present invention,
  • a method for detecting an asthma-causing antigen which is determined to include an asthma-causing antigen in a sample.
  • T cells derived from individuals diagnosed as non-atopic asthma can detect the presence of a causative antigen specific to non-atopic asthma in test samples. can do.
  • Example 1 Induction of IL-5 Production by Peripheral Blood Mononuclear Cells in Patients with Non-Atopic Asthma by an Antigen and Inhalation Induction by Each Antigen
  • Venous blood was collected from 30 asthmatic patients, and peripheral blood mononuclear cells (PBMC) were separated by Ficoll-Paque specific gravity centrifugation.
  • the cells were suspended in AIM-V medium (Gibco BRL) at 2 ⁇ 10 ⁇ cells / ⁇ l and cultured in a 24 ⁇ l plate (manufactured by Koning).
  • AIM-V medium Gibco BRL
  • a physiological saline solution of the antigen [Candida extract (manufactured by Torii Pharmaceutical Co., Ltd.)] was added and stimulated so that the final concentration of the antigen was 10 gZml.
  • physiological saline alone was added instead of the physiological saline solution of the antigen.
  • the culture supernatant was collected and the amount of IL-5 was measured by ELISA, and the difference between the case of stimulation with the antigen and the case of the control was examined.
  • the increase in IL-5 production induced by Candida extract was less than 20 pg / m1 in 254 patients (Group A), while it was 20 pg / m1 or more in 55 patients (Group B). Showed an increase in IL-5 production.
  • the average age of patients in group A was 47.0 ⁇ 1.1 years
  • the average increase in IL-5 was 9.7 ⁇ 0.6 pgZml
  • the average age of patients in group B was 46.2 ⁇ 2.
  • the average increase in IL-15 at age 2 was 142.3 ⁇ 34.9 pg / ml.
  • venous blood was collected again from six patients with normal values (RA STfiO. 35 PRU / ml or less) based on the measurement of antigen-specific IgE antibodies in serum.
  • PBMC was separated by specific gravity centrifugation.
  • the cells were suspended in AIM-V medium at 2 ⁇ 10 6 cells / well and cultured in a 24-well plate.
  • Various antigens Candida extract, tick extract (Torii Pharmaceutical Co., Ltd.), Candida albicans-derived secreted acidic protease (Candida acid protease, Takara Shuzo)
  • the inhalation induction test was performed in accordance with the Japanese Society of Allergology standard method.
  • the subject's respiratory function before loading was measured using Peakman 8 (manufactured by Chiis Giken) under maximum expiratory effort.
  • Inhalation was performed by using a nebulizer (Devilbiss) and injecting 5 LZmin of compressed air for 2 minutes. After inhaling physiological saline alone as a control and confirming that there was no decrease in respiratory function, 1 g / m1 for Candida acid protease, and a 10,000-fold diluted aqueous solution for tick extract and power plant extract were used. After inhalation for 2 minutes, respiratory function was measured 10 minutes later.
  • the respiratory function was measured 10 minutes after the inhalation load of the antigen solution, and thereafter, the respiratory function was measured every hour for delayed asthmatic reactions. The results are shown in Table 1. In both cases of IAR and LAR, if it is 5%, it is determined that the reaction is not recognized.
  • Antigen I L-5 (pg / ml)
  • Example 2 Induction of IL-15 production and lymphocyte (T cell) proliferation by Candida-derived antigens against PBMC in patients with non-atopic asthma
  • each antigen is 10 / g / ml in a saline solution of each Candida-derived antigen [Candida extract, Candida acid protease, Candida mannan A (Candida, albicans-derived cell wall typeA mannan, manufactured by Takara Shuzo)]. As well as stimulated.
  • Fig. 1 shows the results for eight cases (5 cases for Candida mannan A) that reacted against Candida-derived antigens. In FIG. 1, the difference is referred to as IL-15 production (pgZm1). Put on.
  • AIM- the PB MC suspended in V medium was placed in a 1 X 1 0'll be 5 cells / Uweru sea urchin 9 6 ⁇ El plate.
  • the antigen was added to 10 ⁇ g / ml, and after culturing for 6 days, 3 H-thymidine (0.5 CiZ perl) was added. After 18 hours of culture, the cells were collected, and the amount of 3 H-thymidine incorporation into the cells was measured as an indicator of T cell proliferation.
  • physiological saline alone was added instead of the physiological saline solution of the antigen.
  • Fig. 2 shows the results for eight cases (5 cases for Candida mannan A) that react with Candida-derived antigens.
  • the following components are individually packaged to produce a kit for identifying the antigen causing asthma.
  • a therapeutic agent for non-atopic asthma (antisensitizing therapeutic antigen) is produced according to a known method.
  • Candida albicans-derived acid protease (freeze-dried product) is dissolved in physiological saline to which 0.5% phenol is added, and this is used as a stock solution of an antigen for the treatment of desensitization. In treatment, the above stock solution is diluted appropriately before use.
  • a method for identifying an antigen causing asthma which is capable of identifying an antigen causing asthma, particularly non-atopic asthma.
  • a kit for identifying an asthma-causing antigen which can easily and quickly identify an asthma-causing antigen.
  • a therapeutic or preventive agent for non-atopic asthma which comprises an asthma-causing antigen which can be identified by the identification method and the like.
  • the present invention provides a method for detecting an asthma-causing antigen capable of detecting the presence of an asthma-causing antigen in a test sample. Therefore, the present invention provides a very useful technique in the field of industry related to the treatment and prevention of asthma, especially non-atopic asthma.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé d'identification d'un antigène responsable de l'asthme dans lequel on utilise la production de IL-5 par des lymphocytes T provoquée par la stimulation avec l'antigène en tant qu'indicateur. L'invention concerne également une trousse permettant l'identification de l'antigène responsable, des méthodes de traitement et de prévention. En outre, l'invention concerne un procédé de détection d'un antigène responsable de l'asthme.
PCT/JP2002/001403 2001-02-22 2002-02-19 Procede de detection d'un antigene responsable de l'asthme Ceased WO2002066979A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002566654A JPWO2002066979A1 (ja) 2001-02-22 2002-02-19 気管支喘息原因抗原の検出方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001047433 2001-02-22
JP2001-47433 2001-02-22

Publications (1)

Publication Number Publication Date
WO2002066979A1 true WO2002066979A1 (fr) 2002-08-29

Family

ID=18908863

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/001403 Ceased WO2002066979A1 (fr) 2001-02-22 2002-02-19 Procede de detection d'un antigene responsable de l'asthme

Country Status (2)

Country Link
JP (1) JPWO2002066979A1 (fr)
WO (1) WO2002066979A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08114588A (ja) * 1994-10-19 1996-05-07 Taisho Pharmaceut Co Ltd サイトカイン産生抑制剤の簡易評価法
JPH09502969A (ja) * 1993-09-16 1997-03-25 アラージェン インコーポレイテッド アレルゲンに対するホストの免疫応答を調節するための方法および組成物
JPH10123133A (ja) * 1996-10-24 1998-05-15 Sekisui Chem Co Ltd 抗原特異的細胞性免疫応答の測定容器、測定キット及び測定方法
JPH11501807A (ja) * 1995-03-03 1999-02-16 メレニウム ファーマシューティカルズ，インコーポレーテッド 免疫疾患の治療および診断のための組成物および方法
JP2000139495A (ja) * 1998-11-02 2000-05-23 Sekisui Chem Co Ltd Ｔｈ１及びＴｈ２細胞機能の測定方法
JP2000508627A (ja) * 1996-03-21 2000-07-11 インペリアル カレッジ イノヴェーションズ リミテッド 潜在ペプチドならびにそれらの同定方法
JP2000230890A (ja) * 1999-02-10 2000-08-22 Matsushita Electric Ind Co Ltd アレルゲン測定用被検液作成方法およびアレルゲン測定用被検液作成装置

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09502969A (ja) * 1993-09-16 1997-03-25 アラージェン インコーポレイテッド アレルゲンに対するホストの免疫応答を調節するための方法および組成物
JPH08114588A (ja) * 1994-10-19 1996-05-07 Taisho Pharmaceut Co Ltd サイトカイン産生抑制剤の簡易評価法
JPH11501807A (ja) * 1995-03-03 1999-02-16 メレニウム ファーマシューティカルズ，インコーポレーテッド 免疫疾患の治療および診断のための組成物および方法
JP2000508627A (ja) * 1996-03-21 2000-07-11 インペリアル カレッジ イノヴェーションズ リミテッド 潜在ペプチドならびにそれらの同定方法
JPH10123133A (ja) * 1996-10-24 1998-05-15 Sekisui Chem Co Ltd 抗原特異的細胞性免疫応答の測定容器、測定キット及び測定方法
JP2000139495A (ja) * 1998-11-02 2000-05-23 Sekisui Chem Co Ltd Ｔｈ１及びＴｈ２細胞機能の測定方法
JP2000230890A (ja) * 1999-02-10 2000-08-22 Matsushita Electric Ind Co Ltd アレルゲン測定用被検液作成方法およびアレルゲン測定用被検液作成装置

Also Published As

Publication number Publication date
JPWO2002066979A1 (ja) 2004-06-24

Similar Documents

Publication Publication Date Title
Legg et al. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis
Tomkinson et al. The failure of STAT6-deficient mice to develop airway eosinophilia and airway hyperresponsiveness is overcome by interleukin-5
Wilson et al. Allergic sensitization through the airway primes Th17-dependent neutrophilia and airway hyperresponsiveness
GERBLICH et al. Dynamic T-Cell Bronchoalveolar in Asthmatics1-4
Csernok et al. Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation
Knutsen et al. Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis
Gilbert et al. Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84
White et al. Neutrophils and mast cells. I. Human neutrophil-derived histamine-releasing activity.
Kallal et al. CCL20/CCR6 blockade enhances immunity to RSV by impairing recruitment of DC
Alam et al. The magnitude of the spontaneous production of histamine-releasing factor (HRF) by lymphocytes in vitro correlates with the state of bronchial hyperreactivity in patients with asthma
Aricha et al. Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor
Grzegorczyk et al. Increased apoptosis of peripheral blood mononuclear cells in patients with perennial allergic asthma/rhinitis: relation to serum markers of apoptosis
Juliusson et al. Macrophages on the nasal mucosal surface in provoked and naturally occurring allergic rhinitis
Schnaper et al. Steroid-sensitive mechanism of soluble immune response suppressor production in steroid-responsive nephrotic syndrome.
CN107109476A (zh) 用于毛细支气管炎后哮喘诊断的标志物及其用途
Schauer et al. Enhanced leukotriene C4 production by peripheral eosinophilic granulocytes from children with asthma
WO2002066979A1 (fr) Procede de detection d'un antigene responsable de l'asthme
CONDINO-NETO et al. Effect of therapy with recombinant human interferon-γ on the release of nitric oxide by neutrophils and mononuclear cells from patients with chronic granulomatous disease
Niimi et al. Late respiratory response and associated eosinophilic inflammation induced by repeated exposure to toluene diisocyanate in guinea pigs
JP5175198B2 (ja) インターフェロンを用いる肺疾患の処置方法
Garty et al. Systemic meningococcal infections in patients with acquired complement deficiency
Hol et al. IgM in the airways of asthma patients
Papadakis et al. Insights into atopic dermatitis–from pathogenesis to therapy
Kojima et al. Improvement with disodium cromoglycate of neutrophil phagocytosis and respiratory burst activity in a patient with hyperimmunoglobulin E syndrome
Ebo et al. The basophil activation test in the diagnosis and follow-up of hymenoptera venom allergy: an alternative point of view

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002566654

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase